SCHAUMBURG, Ill., Jan. 31, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2012 fourth quarter and fiscal year end pre-market on Thursday, February 14, 2013 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Interested parties may access the live call by dialing:
Within the United States: 877-293-5456
A live webcast of the teleconference will be available on the company's website at: http://investor.sagentpharma.com/events.cfm.
A replay of the presentation will be available on the Sagent website or by dialing:
The replay will be available until February 28, 2013.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
CONTACT: SAGENT CONTACT: Jonathon Singer (847) 908-1605
|Hill International Schedules Release of Fourth Quarter and Full Year 2012 Financial Results and Conference Call (2013/2/11)|
|Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2013 Financial Results (2013/4/24)|
|Aurora Announces Release Date for Fourth Quarter and Full-year 2012 Financial Results and Market Briefing Conference Call (2013/2/20)|
|Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results (2013/3/4)|
|Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013 (2013/2/26)|
|AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results (2013/3/12)|
|TeleTech Announces Release Date for Fourth Quarter and Full Year 2012 Financial Results and Filing of Its Annual Report on Form 10-K (2013/2/5)|
|Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results (2013/3/27)|
|Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Update on Autoimmune Disease Program (2013/3/11)|
|Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results (2013/3/7)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.